Another A-share company is planning a major asset restructuring. On the evening of October 17, 威高血净 (Shandong Weigao Blood Purification Products Co., Ltd.) announced that the company is in the process of acquiring 100% of the equity of 山东威高普瑞医药包装有限公司 (Shandong Weigao Pri-Medical Packaging Co., Ltd.) through a share issuance (hereinafter referred to as "the transaction").
Upon completion of this transaction, 威高普瑞 (Weigao Pri) will become a wholly-owned subsidiary of 威高血净. According to the Measures for the Administration of Major Asset Restructuring of Listed Companies and other relevant laws and regulations, the preliminary assessment suggests that the transaction constitutes a major asset restructuring and is a related party transaction. This transaction will not result in a change in the actual controller of the company and does not constitute a restructuring listing.
In the announcement, 威高血净 disclosed that the transaction is still in the planning stage, and related matters remain uncertain. In order to protect investor interests, ensure fair information disclosure, and avoid significant impacts on the company's stock price, the company's shares will be suspended from trading starting October 20, 2025 (Monday), with the suspension expected to last no more than 10 trading days.
Looking at the target of the transaction, 威高普瑞 was established on September 13, 2018, with a legal representative named 龙经. It has a registered capital of 106 million yuan, and its business scope includes the production and sales of Class I and Class II medical devices, as well as the manufacture and sale of medical packaging materials. The transaction counterparties are 山东威高集团医用高分子制品股份有限公司 (Shandong Weigao Group Medical Polymer Products Co., Ltd.), 威海盛熙企业管理咨询中心（有限合伙） (Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership)), and 威海瑞明企业管理咨询合伙企业（有限合伙） (Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership)).
Regarding the equity structure, data from 企业查查 (Qichacha) indicates that 山东威高集团医用高分子制品股份有限公司 is the largest shareholder, holding 94% of the shares, while the major shareholder of the former is 威高集团 (Weigao Group).
According to its official website, 威高普瑞 is a subsidiary of 威高集团 and is the first manufacturer in China to obtain a registration certificate for pre-filled syringes, continuously introducing the latest international production lines and product technologies for pre-filled syringes. The product range covers the entire series of pre-filled syringes.
威高血净 was listed on the Shanghai Stock Exchange on May 19 this year, focusing on the research and development, production, and sales of blood purification medical products since its establishment. Its main products include blood dialysis machines, blood dialysis lines, and peritoneal dialysis fluids, catering to both hemodialysis and peritoneal dialysis fields, supported by a wide range of dialysis-related products. This makes it one of the domestic manufacturers with the most extensive product line for blood purification medical products.
As of the end of June this year, 威高集团 holds 41.75% of the shares as the largest shareholder of 威高血净; 山东威高集团医用高分子制品股份有限公司 holds 23.9% as the second largest shareholder. The actual controller of the company is 陈学利 (Chen Xueli).
In terms of operating performance, 威高血净 reported a half-year financial report for 2025 on the evening of August 27, showing that the company's operating income for the first half of the year was 1.765 billion yuan, an increase of 8.52% year-on-year; net profit attributable to the parent company was 220 million yuan, a year-on-year increase of 10.11%; and net profit excluding non-recurring gains and losses was 215 million yuan, an increase of 9.64% year-on-year.
Comments